Vasoactive intestinal peptide protects alveolar epithelial cells against hyperoxia via promoting the activation of STAT3

Regulatory Peptides

Volumn 168, Issue 1-3, 2011, Pages 1-4

  Ao, Xiaoxiao ^a   Fang, Fang ^a   Xu, Feng ^a  

^a CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Hyperoxia; Signal transducers and activators of transcription; Type II alveolar epithelial cell; Vasoactive intestinal peptide

Indexed keywords

FLUORESCENT DYE; STAT3 PROTEIN; TRANSFER RNA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HYPEROXIA; LUNG ALVEOLUS EPITHELIUM; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; WILD TYPE;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; EPITHELIAL CELLS; HYPEROXIA; MICE; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; PULMONARY ALVEOLI; STAT3 TRANSCRIPTION FACTOR; VASOACTIVE INTESTINAL PEPTIDE;

EID: 79955649977     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.02.006     Document Type: Article

References (28)

1. Altemeier W.A., Sinclair S.E. Hyperoxia in the intensive care unit: why more is not always better. Curr Opin Crit Care 2007, 13(1):73-78.
2. Miyake Y., Kaise H., Isono K., Kohno K., Tanaka M. Protective role of macrophages in noninflammatory lung injury caused by selective ablation of alveolar epithelial type II cells. J Immunol 2007, 178:5001-5009.
3. Mantell L.L., Lee P.J. Signal transduction pathway in hyperoxia-induced lung cell death. Mol Genet Metab 2000, 71:359-370.
4. Franek W.R., Morrow D.M., Zhu H., Van Test I. article sample title placed here. Free Radic Biol Med 2004, 37(10):1670-1679.
5. Lee P.J., Camhi S.L., Chin B.Y., Alam J., Choi A.M. AP-1 and STAT mediate hyperoxia -induced gene transcription of heme oxygenase-1. Am J Physiol Lung Cell Mol Physiol 2000, 279(1):175-182.
6. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999, 98(3):295-303.
7. Bowman T., Garcia R., Urkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19(21):2474-2488.
8. Hodge D.R., Hurt E.M., Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005, 41:2502-2512.
9. Akeda K., Akira S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 2000, 11(3):199.
10. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., Vaudry H. Pituitary adenylate cyclase activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 2000, 52:269-324.
11. Onoue S., Yamada S., Yajima T. Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD. Peptides 2007, 28:1640-1650.
12. Onuoha G.N., Alpar E.K., Jones I. Vasoactive intestinal peptide and nitric oxide in the acute phase following burns and trauma. Burns 2001, 27(1):17-21.
13. Said S.I. The Viktor Mutt memorial lecture protection by VIP and related peptides against cell and tissue injury. Ann NY Acad Sci 2000, 921:264-274.
14. Absood A., Hu B., Bassily N., Colletti L. VIP inhibits human HepG2 cell proliferation in vitro. Regul Pept 2008, 146(1-3):285-292.
15. Fraccaroli L., Grasso E., Zeitler E., Lombardi E., Gogorza S., Etchepareborda J.J., et al. Modulation of maternal LIF producers T cells by trophoblast and paternal antigens. Am J Reprod Immunol 4 Jul 2010.
16. Altemeier W.A., Sinclair S.E. Hyperoxia in the intensive care unit: why more is not always better. Curr Opin Crit Care 2007, 13(1):73-78.
17. Geiser T. Mechanisms of alveolar epithelial repair in acute lung injury-a translational approach. Swiss Med Wkly 2003, 133(43-44):586-590.
18. Zaher T.E., Miller E.J., Morrow D.M., Javdan M., Mantell L.L. Hyperoxia-induced signal transduction pathways in pulmonary epithelial cells. Free Radic Biol Med 2007, 42(7):897-908.
19. Jiang J., Xu F., Chen J. Repair, survival and apoptosis of type II alveolar epithelial cells and the change of bcl-2/p53 in oxidative stress. Zhonghua Er Ke Za Zhi 2008, 46:74-75.
20. Huang B., Fu H., Yang M., Fang F., Kuang F., Neuropeptide F.Xu. substance P attenuates hyperoxia-induced oxidative stress injury in type II alveolar epithelial cells via suppressing the activation of JNK pathway. Lung 2009, 187(6):421-426.
21. Maggi C.A., Giachetti A., Dey R.D., Said S.I. Neuropeptide as regulators of airway function: vasoactive intestinal peptide and tachykinin. Physiol Rev 1995, 75(2):277-322.
22. Koh S.W., Cheng J., Dodson R.M., Ku C.Y., Abbondandolo C.J. VIP down-regulates the inflammatory potential and promotes survival of dying (neural crest-derived) corneal endothelial cells ex vivo: necrosis to apoptosis switch and up-regulation of Bcl-2 and N-cadherin. J Neurochem 2009, 109(3):792-806.
23. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat Med 2000, 6(5):513-519.
24. Sakon S., Xue X., Takekawa M., Sasazuki T., Okazaki T., Kojima Y., et al. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 2003, 22:3898-3909.
25. Darnell J.E. Validating Stat3 in cancer therapy. Nat Med 2005, 11(6):623-629.
26. Liu X. STAT3 activation inhibits human bronchial epithelial cell apoptosis in response to cigarette smoke exposure. Biochem Biophys Res Commun 2007, 353(1):121-126.
27. Lian X., Qin Y., Hossain S.A., Yang L., White A., Xu H., et al. Overexpression of Stat3C in pulmonary epithelium protects against hyperoxic lung injury. J Immunol 2005, 174(11):7250-7256.
28. Simon A.R., Rai U., Fanburg B.L., Cochran B.H. Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol 1998, 275(6 Pt 1):C1640-C1652.